Climb Bio (CLYM) Profit After Tax (2020 - 2026)

Climb Bio (CLYM) has 7 years of Profit After Tax data on file, last reported at -$14.0 million in Q1 2026.

• Quarterly Profit After Tax rose 32.63% year-over-year to -$14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.1 million (up 42.93% YoY) and the FY2025 annual result came in at -$59.9 million, up 19.01% from the prior year.
• Profit After Tax climbed to -$14.0 million in Q1 2026, from -$17.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$1.7 million in Q1 2024 to a low of -$54.9 million in Q2 2024.
• A 5-year average of -$13.4 million and a median of -$9.7 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 92.39% — and 2025, when it sank 1124.57%.
• Tracing CLYM's Profit After Tax over 5 years: stood at -$7.5 million in 2022, then jumped by 51.82% to -$3.6 million in 2023, then sank by 137.31% to -$8.6 million in 2024, then plunged by 103.23% to -$17.5 million in 2025, then climbed by 20.07% to -$14.0 million in 2026.
• The last three Profit After Tax figures came in at -$14.0 million (Q1 2026), -$17.5 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.